August 04, 2023 – We at thasso recently had an article (blog) on the much discussed and recently throughout the social media as wonder compound (drug) for weight loss promoted active ingredient Semaglutide in the form of the newly marketed product …

Is there living pharmacogenovigilance behind Semaglutide drugs? Read more »

August 03, 2019 – Africa is considered the original cradle of all humanity, to which all humans can trace their genetic origin. This may be very interesting in the context of diseases that are due to genetic predispositions both in …

ZRANB3 in African Populations: New Type 2 Diabetes risk locus identified Read more »

August 12, 2018 – Findings from a retrospective case-control study were published online August 8, 2018, in JAMA Dermatology indicate that the use of certain dipeptidyl peptidase 4 (DPP-4) inhibitor drugs are associated with a small but significantly elevated risk for developing bullous …

Risk of Bullous Pemphigoid with Type 2 Diabetes Drugs Read more »

July 07, 2017 – A new study analyzing genetic mutations predisposing to increased body-mass index (BMI) provides strong evidence that higher BMI plays a causal role in type 2 diabetes, hypertension, and coronary heart disease (CHD). The study results strongly suggest …

Genetic Study Strengthens Causal Role of BMI in Heart Disease Read more »

August 01, 2016 – Type 2 diabetes affects more than 29 million people and accounts for more than 90 percent of diabetes cases diagnosed in the United States. Over time, high blood sugar levels can increase the risk for serious …

Lixisenatide (Adlyxin) approved to treat type 2 diabetes Read more »

June 16, 2016 – The sodium-glucose cotransporter 2 (SGLT2) is a protein that is encoded by the SLC5A2 gene. SGLT2 is one member of a larger family of sodium-glucose cotransporters which are sodium-dependent glucose transport proteins. SGLT2 is the major cotransporter involved in glucose reabsorption in the kidney. SGLT2 inhibitors are called gliflozins and …

Sodium-glucose cotransporter-2 (SGLT2) inhibitors in Type-2 Diabetes: Risk of acute kidney injury Read more »

February 14, 2016 – Diabetic ketoacidosis is a serious complication of diabetes caused by low insulin levels. Rare cases of this condition, including life-threatening ones, have occurred in patients taking SGLT2 inhibitors for type 2 diabetes and a number of these cases have …

SGLT2 inhibitors and diabetic ketoacidosis: PRAC makes recommendations to minimise risk to patients Read more »

December 5, 2015 – A safety review by the American Food and Drug Administration (FDA) has resulted in the addition of specific warnings to the drug labels of a specific class of type 2 diabetes medicines called sodium-glucose cotransporter-2 (SGLT2) inhibitors …

SGLT2 Inhibitors and ketoacidosis: Warnings about too much acid in the blood and serious urinary tract infections included in new drug labels Read more »

October 28, 2015 – According to a  small prospective and randomized clinical study, just published online in the Annals of Internal Medicine, a regularly taken glass of wine with dinner may improve lipid and glycemic control profiles in patients with type 2 …

Theragenomic medicine and social habits: A regularly taken glass of wine may improve cardiometabolic risks in some patients with type 2 diabetes Read more »

Decreased Bone Density (right panel)

 September 12, 2015 – Drug Safety Information: The American Food and Drug Administration (FDA)  has just strengthened the warning for the type 2 diabetes medicines containing  canagliflozin as active ingredient, i.e. Invokana and Invokamet, related to the increased risk of bone …

Type 2 Diabetes: Risk for bone fracture and decreased bone mineral density under canagliflozin therapy Read more »